1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Telephone/postal reminders do not improve pravastatin compliance |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
L 651582 + paclitaxel: potential activity against solid tumours |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Micafungin: a novel antifungal agent for invasive infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 7-8
Pamela Hunter,
Preview
|
|
摘要:
Phase II data on micafungin [FK463] were presented recently at the 22nd International Congress of Chemotherapy [Amsterdam, The Netherlands; July 2001] showing that this novel antifungal is highly effective in the treatment of oropharyngeal and oesophageal candidiasis in patients with AIDS. Summary data on over 1300 patients indicate an excellent tolerability profile, with a maximum tolerated dose of 8 mg/kg in adults.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Donepezilvsrivastigmine in AD - same benefits, different downsides |
|
Inpharma Weekly,
Volume &NA;,
Issue 1300,
2001,
Page 11-12
Richard Black,
Preview
|
|
摘要:
The first head-to-head comparison of the Alzheimer's drugs donepezil and rivastigmine has shown some advantages for the former, according to research presented at this year's World Congress of Neurology [London, UK; June 2001]. In a randomised study, patients who took donepezil reported fewer adverse events than those on rivastigmine, although the cognitive benefits of the two drugs were similar.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|